KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Net Cash Flow (2016 - 2025)

Biomarin Pharmaceutical's Net Cash Flow history spans 17 years, with the latest figure at $60.4 million for Q4 2025.

  • For the quarter ending Q4 2025, Net Cash Flow fell 77.22% year-over-year to $60.4 million, compared with a TTM value of $371.4 million through Dec 2025, up 103.06%, and an annual FY2025 reading of $371.4 million, up 103.06% over the prior year.
  • Net Cash Flow for Q4 2025 was $60.4 million at Biomarin Pharmaceutical, up from $35.6 million in the prior quarter.
  • The five-year high for Net Cash Flow was $264.9 million in Q4 2024, with the low at -$293.8 million in Q3 2024.
  • Average Net Cash Flow over 5 years is $32.9 million, with a median of $17.7 million recorded in 2021.
  • Year-over-year, Net Cash Flow tumbled 947.55% in 2023 and then skyrocketed 1167.58% in 2025.
  • Tracing BMRN's Net Cash Flow over 5 years: stood at -$29.8 million in 2021, then fell by 24.16% to -$37.1 million in 2022, then grew by 28.11% to -$26.6 million in 2023, then surged by 1094.33% to $264.9 million in 2024, then plummeted by 77.22% to $60.4 million in 2025.
  • Per Business Quant, the three most recent readings for BMRN's Net Cash Flow are $60.4 million (Q4 2025), $35.6 million (Q3 2025), and $168.1 million (Q2 2025).